EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Immunologic tumor microenvironment modulators for turning cold tumors hot

Gholam-Reza Khosravi, Samaneh Mostafavi, Sanaz Bastan, Narges Ebrahimi, Roya Safari Gharibvand, Nahid Eskandari iD

Cancer Communications · 2024-05 · 44 (5) · 521-553

DOI: 10.1002/cac2.12539 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Communications, online erschienen am 29.03.2024. Verfasst von Gholam-Reza Khosravi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. Hauptthemen laut MEDLINE: Tumor Microenvironment, Neoplasms. Die Arbeit wurde bisher 398-mal zitiert (Crossref) und nennt 281 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tumors can be classified into distinct immunophenotypes based on the presence and arrangement of cytotoxic immune cells within the tumor microenvironment (TME). Hot tumors, characterized by heightened immune activity and responsiveness to immune checkpoint inhibitors (ICIs), stand in stark contrast to cold tumors, which lack immune infiltration and remain resistant to therapy. To overcome immune evasion mechanisms employed by tumor cells, novel immunologic modulators have emerged, particularly ICIs targeting cytotoxic T‐lymphocyte‐associated protein 4 (CTLA‐4) and programmed cell death protein 1/programmed death‐ligand 1(PD‐1/PD‐L1). These agents disrupt inhibitory signals and reactivate the immune system, transforming cold tumors into hot ones and promoting effective antitumor responses. However, challenges persist, including primary resistance to immunotherapy, autoimmune side effects, and tumor response heterogeneity. Addressing these challenges requires innovative strategies, deeper mechanistic insights, and a combination of immune interventions to enhance the effectiveness of immunotherapies. In the landscape of cancer medicine, where immune cold tumors represent a formidable hurdle, understanding the TME and harnessing its potential to reprogram the immune response is paramount. This review sheds light on current advancements and future directions in the quest for more effective and safer cancer treatment strategies, offering hope for patients with immune‐resistant tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor MicroenvironmentNeoplasmsHumansImmune Checkpoint InhibitorsImmunotherapyAnimals

Stichwörter der Autor:innen

cold tumorhot tumorimmunologic modulatorimmunotherapytherapeutic strategytumor microenvironment

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Medical Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
  • Department of Immunology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
  • Department of Immunology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

ORCID-Profile: Nahid Eskandari

Zitieren

APA

Khosravi, G. R., Mostafavi, S., Bastan, S., Ebrahimi, N., Gharibvand, R. S., & Eskandari, N. (2024). Immunologic tumor microenvironment modulators for turning cold tumors hot. Cancer Communications, 44(5), 521-553. https://doi.org/10.1002/cac2.12539

Vancouver

Khosravi GR, Mostafavi S, Bastan S, Ebrahimi N, Gharibvand RS, Eskandari N. Immunologic tumor microenvironment modulators for turning cold tumors hot. Cancer Communications. 2024;44(5):521-553. doi:10.1002/cac2.12539

BibTeX
@article{Khosravi2024,
  author = {Khosravi, Gholam-Reza and Mostafavi, Samaneh and Bastan, Sanaz and Ebrahimi, Narges and Gharibvand, Roya Safari and Eskandari, Nahid},
  title = {Immunologic tumor microenvironment modulators for turning cold tumors hot},
  journal = {Cancer Communications},
  year = {2024},
  volume = {44},
  number = {5},
  pages = {521--553},
  doi = {10.1002/cac2.12539}
}
Kostenlos starten →